Lyndsey Linke, PhD, is the CEO and Co-Founder of SiVEC Biotechnologies, a company pioneering first-in-class therapies in oncology and gene-editing using its proprietary BactPac™ delivery platform. With over 15 years of R&D experience in biotherapeutics and drug delivery, she is the first-named inventor on 33 patents related to SiVEC’s technology. Dr. Linke has raised over $7 million in funding and was recognized as an Inspiring Female Founder and a Top Emerging Company Leader at BIO International 2022.
SiVEC’s BactPac™ platform uses engineered bacteria to safely and precisely deliver biologics—including mRNA, siRNA, proteins, and gene editors—outperforming traditional viral and nanoparticle systems. The company’s lead asset, SVC-KRAb™, is a pan-RAS biologic targeting a wide range of RAS mutations common in hard-to-treat cancers like lung, colorectal, and pancreatic, with the potential to overcome resistance and avoid toxicity—positioning it as a best-in-class RAS-targeting therapy.
In addition to leading SiVEC, Dr. Linke serves as Chairman of the Board and is a Board Member of the Colorado Bioscience Association. She holds a PhD in Epidemiology and a Master’s in Biomedical Engineering from Colorado State University—and is also a former U.S. Olympic Swimming Trials qualifier and nine-time U.S. Masters National Champion.
